Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)

Ye Li; Rafet Basar; Guohui Wang; Enli Liu; Judy S. Moyes; Li Li; Lucila Nassif Kerbauy; Nadima Uprety; Mohsen Fathi; Ali Rezvan; Pinaki P. Banerjee; Luis Muniz-Feliciano; Tamara Jatoba Laskowski; Emily Ensley; May Daher; Mayra Shanley; Mayela Carolina Mendt Vilchez; Sunil Acharya; Bin Liu; Alexander Biederstädt; Hind Rafei; Xingliang Guo; Luciana Melo Garcia; Paul Lin; Sonny Ang; David Marin; Ken Chen; Laura Bover; Richard E. Champlin; Navin Varadarajan; Elizabeth J. Shpall; Katayoun Rezvani

doi:10.1038/s41591-023-02770-1

Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)

Ye Li, Rafet Basar, Guohui Wang, Enli Liu, Judy S. Moyes, Li Li, Lucila Nassif Kerbauy, Nadima Uprety, Mohsen Fathi, Ali Rezvan, Pinaki P. Banerjee, Luis Muniz-Feliciano, Tamara Jatoba Laskowski, Emily Ensley, May Daher, Mayra Shanley, Mayela Carolina Mendt Vilchez, Sunil Acharya, Bin Liu, Alexander BiederstädtHind Rafei, Xingliang Guo, Luciana Melo Garcia, Paul Lin, Sonny Ang, David Marin, Ken Chen, Laura Bover, Richard E. Champlin, Navin Varadarajan, Elizabeth J. Shpall, Katayoun Rezvani

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-022-02003-x, published online 29 September 2022. In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	906
Number of pages	1
Journal	Nature medicine
Volume	30
Issue number	3
DOIs	https://doi.org/10.1038/s41591-023-02770-1
State	Published - Mar 2024

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-023-02770-1

Cite this

Li, Y., Basar, R., Wang, G., Liu, E., Moyes, J. S., Li, L., Kerbauy, L. N., Uprety, N., Fathi, M., Rezvan, A., Banerjee, P. P., Muniz-Feliciano, L., Laskowski, T. J., Ensley, E., Daher, M., Shanley, M., Mendt Vilchez, M. C., Acharya, S., Liu, B., ... Rezvani, K. (2024). Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x). Nature medicine, 30(3), 906. https://doi.org/10.1038/s41591-023-02770-1

Li, Y , Basar, R, Wang, G, Liu, E, Moyes, JS, Li, L, Kerbauy, LN, Uprety, N, Fathi, M, Rezvan, A, Banerjee, PP, Muniz-Feliciano, L, Laskowski, TJ, Ensley, E, Daher, M , Shanley, M, Mendt Vilchez, MC, Acharya, S , Liu, B, Biederstädt, A, Rafei, H , Guo, X, Melo Garcia, L, Lin, P , Ang, S , Marin, D , Chen, K, Bover, L, Champlin, RE, Varadarajan, N, Shpall, EJ & Rezvani, K 2024, 'Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)', Nature medicine, vol. 30, no. 3, pp. 906. https://doi.org/10.1038/s41591-023-02770-1

@article{ba0db9df12ec472e985526e85068594a,

title = "Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)",

abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-022-02003-x, published online 29 September 2022. In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article.",

author = "Ye Li and Rafet Basar and Guohui Wang and Enli Liu and Moyes, {Judy S.} and Li Li and Kerbauy, {Lucila Nassif} and Nadima Uprety and Mohsen Fathi and Ali Rezvan and Banerjee, {Pinaki P.} and Luis Muniz-Feliciano and Laskowski, {Tamara Jatoba} and Emily Ensley and May Daher and Mayra Shanley and {Mendt Vilchez}, {Mayela Carolina} and Sunil Acharya and Bin Liu and Alexander Biederst{\"a}dt and Hind Rafei and Xingliang Guo and {Melo Garcia}, Luciana and Paul Lin and Sonny Ang and David Marin and Ken Chen and Laura Bover and Champlin, {Richard E.} and Navin Varadarajan and Shpall, {Elizabeth J.} and Katayoun Rezvani",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.",

year = "2024",

month = mar,

doi = "10.1038/s41591-023-02770-1",

language = "English (US)",

volume = "30",

pages = "906",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Correction to

T2 - KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)

AU - Li, Ye

AU - Basar, Rafet

AU - Wang, Guohui

AU - Liu, Enli

AU - Moyes, Judy S.

AU - Li, Li

AU - Kerbauy, Lucila Nassif

AU - Uprety, Nadima

AU - Fathi, Mohsen

AU - Rezvan, Ali

AU - Banerjee, Pinaki P.

AU - Muniz-Feliciano, Luis

AU - Laskowski, Tamara Jatoba

AU - Ensley, Emily

AU - Daher, May

AU - Shanley, Mayra

AU - Mendt Vilchez, Mayela Carolina

AU - Acharya, Sunil

AU - Liu, Bin

AU - Biederstädt, Alexander

AU - Rafei, Hind

AU - Guo, Xingliang

AU - Melo Garcia, Luciana

AU - Lin, Paul

AU - Ang, Sonny

AU - Marin, David

AU - Chen, Ken

AU - Bover, Laura

AU - Champlin, Richard E.

AU - Varadarajan, Navin

AU - Shpall, Elizabeth J.

AU - Rezvani, Katayoun

PY - 2024/3

Y1 - 2024/3

N2 - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-022-02003-x, published online 29 September 2022. In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-022-02003-x, published online 29 September 2022. In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85181509498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181509498&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02770-1

DO - 10.1038/s41591-023-02770-1

M3 - Comment/debate

C2 - 38182787

AN - SCOPUS:85181509498

SN - 1078-8956

VL - 30

SP - 906

JO - Nature medicine

JF - Nature medicine

IS - 3

ER -

Correction to: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape (Nature Medicine, (2022), 28, 10, (2133-2144), 10.1038/s41591-022-02003-x)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this